Company intelligence / Profile preview

Surgilogix

United States

Ownership: Private
Employees: ~13
Development stage: Other

Overview

Surgilogix offers FDA-regulated human tissue allografts based on amniotic tissue and bone for regenerative medicine applications, with clinical use focused on wound healing, bone defects, and tissue repair in several specialties. There is published research showing the efficacy of their products in wound healing applications with live amniotic-derived stem cells in amnion matrix liquid allografts[1][2][3][5].

Therapeutic areas: OtherWomen's HealthNeurologyDermatologyRheumatologyMen's Health
Modalities: Human tissue allograftAmniotic tissueBone allograftAmniotic-derived stem cells
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Surgilogix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surgilogix.

Explore the full profile